ICL to Acquire the Activity of Evogene's Subsidiary, Lavie Bio
Evogene (Nasdaq: EVGN) has announced a definitive agreement for ICL to acquire the majority of activities of its subsidiary, Lavie Bio , along with Evogene's MicroBoost AI for AG platform. The transaction is expected to close in Q2 2025.
The acquisition includes Lavie Bio's core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. Lavie Bio's existing partner agreements will remain with current shareholders. This deal follows ICL Planet's strategic investment and over two years of collaboration between ICL and Lavie Bio in developing bio-stimulant solutions for row crops.
Lavie Bio specializes in microbiome-based ag-biological products aimed at improving agricultural productivity and sustainability. The integration aims to accelerate the development of innovative agricultural solutions globally.
Evogene (Nasdaq: EVGN) ha annunciato un accordo definitivo per l'acquisizione da parte di ICL della maggior parte delle attività della sua controllata, Lavie Bio, insieme alla piattaforma MicroBoost AI for AG di Evogene. La transazione è prevista per il secondo trimestre del 2025.
L'acquisizione comprende il team principale di Lavie Bio, la piattaforma tecnologica BDD, la banca microbica, i dati, i programmi di sviluppo e i prodotti commerciali. Gli accordi di partnership esistenti di Lavie Bio rimarranno con gli azionisti attuali. Questo accordo segue l'investimento strategico di ICL Planet e oltre due anni di collaborazione tra ICL e Lavie Bio nello sviluppo di soluzioni bio-stimolanti per colture agricole.
Lavie Bio è specializzata in prodotti ag-biològici basati sul microbioma, volti a migliorare la produttività agricola e la sostenibilità. L'integrazione mira ad accelerare lo sviluppo di soluzioni agricole innovative a livello globale.
Evogene (Nasdaq: EVGN) ha anunciado un acuerdo definitivo para que ICL adquiera la mayoría de las actividades de su subsidiaria, Lavie Bio, junto con la plataforma MicroBoost AI for AG de Evogene. Se espera que la transacción se cierre en el segundo trimestre de 2025.
La adquisición incluye el equipo principal de Lavie Bio, la plataforma tecnológica BDD, el banco microbiano, los activos de datos, los programas de desarrollo y los productos comerciales. Los acuerdos de asociación existentes de Lavie Bio permanecerán con los accionistas actuales. Este acuerdo sigue a la inversión estratégica de ICL Planet y a más de dos años de colaboración entre ICL y Lavie Bio en el desarrollo de soluciones bioestimulantes para cultivos extensivos.
Lavie Bio se especializa en productos agrobiológicos basados en microbiomas, destinados a mejorar la productividad agrícola y la sostenibilidad. La integración busca acelerar el desarrollo de soluciones agrícolas innovadoras a nivel mundial.
Evogene (나스닥: EVGN)는 ICL이 자회사 Lavie Bio의 주요 사업과 Evogene의 MicroBoost AI for AG 플랫폼을 인수하는 최종 계약을 체결했다고 발표했습니다. 거래는 2025년 2분기에 마무리될 예정입니다.
이번 인수에는 Lavie Bio의 핵심 팀, BDD 기술 플랫폼, 미생물 은행, 데이터 자산, 개발 프로그램 및 상업 제품이 포함됩니다. Lavie Bio의 기존 파트너십 계약은 현재 주주와 유지됩니다. 이번 거래는 ICL Planet의 전략적 투자와 ICL과 Lavie Bio 간 2년 이상의 협력 끝에 이루어졌으며, 주로 밭작물용 생체 촉진제 솔루션 개발에 집중했습니다.
Lavie Bio는 농업 생산성과 지속 가능성 향상을 목표로 하는 미생물군집 기반의 농업 생물학적 제품을 전문으로 합니다. 이번 통합은 전 세계적으로 혁신적인 농업 솔루션 개발을 가속화하는 것을 목표로 합니다.
Evogene (Nasdaq : EVGN) a annoncé un accord définitif pour qu'ICL acquière la majorité des activités de sa filiale, Lavie Bio, ainsi que la plateforme MicroBoost AI for AG d'Evogene. La transaction devrait être finalisée au deuxième trimestre 2025.
L'acquisition comprend l'équipe principale de Lavie Bio, la plateforme technologique BDD, la banque microbienne, les données, les programmes de développement et les produits commerciaux. Les accords de partenariat existants de Lavie Bio resteront avec les actionnaires actuels. Cet accord fait suite à l'investissement stratégique d'ICL Planet et à plus de deux ans de collaboration entre ICL et Lavie Bio pour développer des solutions bio-stimulantes pour les cultures de plein champ.
Lavie Bio est spécialisée dans les produits agro-biologiques basés sur le microbiome, visant à améliorer la productivité agricole et la durabilité. L'intégration vise à accélérer le développement de solutions agricoles innovantes à l'échelle mondiale.
Evogene (Nasdaq: EVGN) hat eine endgültige Vereinbarung bekannt gegeben, wonach ICL den Großteil der Aktivitäten seiner Tochtergesellschaft Lavie Bio sowie die MicroBoost AI for AG-Plattform von Evogene übernehmen wird. Der Abschluss der Transaktion wird für das zweite Quartal 2025 erwartet.
Die Übernahme umfasst das Kernteam von Lavie Bio, die BDD-Technologieplattform, die Mikrobenbank, Datenbestände, Entwicklungsprogramme und kommerzielle Produkte. Die bestehenden Partnervereinbarungen von Lavie Bio verbleiben bei den aktuellen Anteilseignern. Dieser Deal folgt auf die strategische Investition von ICL Planet und über zwei Jahre Zusammenarbeit zwischen ICL und Lavie Bio bei der Entwicklung von Bio-Stimulanzien für Feldfrüchte.
Lavie Bio ist auf mikrobiombasierte ag-biologische Produkte spezialisiert, die darauf abzielen, die landwirtschaftliche Produktivität und Nachhaltigkeit zu verbessern. Die Integration soll die Entwicklung innovativer landwirtschaftlicher Lösungen weltweit beschleunigen.
- Strategic acquisition strengthens market position in ag-biologicals sector
- Retention of revenue potential from existing partnership agreements
- Built on established successful collaboration with ICL Planet
- Transaction unlocks immediate value for Evogene shareholders
- Loss of majority control over Lavie Bio's operations
- Divestment of key technological assets including MicroBoost AI platform
Insights
ICL's acquisition of Lavie Bio's operations represents a strategic divestiture for Evogene, unlocking shareholder value through monetization of its subsidiary's assets.
This transaction demonstrates a structured approach to asset monetization by Evogene. The definitive agreement transfers substantial portions of Lavie Bio's operations to ICL, including the core team, BDD technology platform, microbial bank, data assets, development programs, and commercial products. Additionally, Evogene's MicroBoost AI for AG platform will be acquired.
The deal structure includes an important retention element: Lavie Bio's existing partner agreements will remain with the original shareholders, potentially generating future revenue streams. This suggests a thoughtful value preservation mechanism rather than a complete exit.
What's particularly notable is that this transaction follows both a strategic investment by ICL Planet and over two years of collaboration between the companies. This progression from partnership to acquisition indicates a carefully cultivated business relationship that evolved organically.
With an expected closing in Q2 2025 subject to customary conditions, this deal represents the culmination of Evogene's explicitly stated strategy to "unlock the value of its assets for the benefit of its shareholders." While financial terms aren't disclosed, the transaction appears to be a significant milestone in Evogene's corporate development.
The acquisition of Lavie Bio's operations by ICL represents a significant consolidation in the ag-biologicals sector. Lavie Bio has established itself as a recognized leader in microbiome-based agricultural biologicals with a robust product pipeline.
What makes this transaction technically significant is the comprehensive nature of the transferred assets: the BDD technology platform, microbial bank, and data assets represent years of specialized R&D work in agricultural biologicals. These biologicals improve agriculture productivity and sustainability – critical objectives as global farming faces increasing environmental challenges.
The MicroBoost AI for AG platform acquisition is especially noteworthy as it represents Evogene's computational biology capabilities specifically tailored for agricultural applications. This AI-driven platform accelerates discovery and development of microbial-based products that can enhance crop resilience to various stresses.
The previous two-year collaboration between these companies focused specifically on "developing innovative bio-stimulant solutions for row crops facing various abiotic stresses" – addressing a growing market need as climate change increases environmental pressures on agriculture. This prior relationship suggests ICL recognized sufficient value in Lavie Bio's technological approach to move from collaboration to acquisition, potentially accelerating the commercialization of these agricultural biological solutions.
Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products
REHOVOT,
The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.
Lavie Bio is a recognized leader in the ag-biologicals industry with a robust pipeline of microbiome-based ag-biological products. Key assets to be transferred to ICL include Lavie Bio's core team, the BDD technology platform, the company's microbial bank and data assets, the majority of the company's development programs, and its commercial products. Additionally, ICL will acquire Evogene's MicroBoost AI for AG platform. Lavie Bio's existing agreements with its current partners will not be transferred to ICL and may generate future revenue for Lavie Bio's shareholders.
This transaction follows strategic investment by ICL Planet and more than two years of close collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for row crops facing various abiotic stresses.
"Today marks a significant milestone in Lavie Bio's journey," said Amit Noam, CEO of Lavie Bio. "By combining our capabilities with ICL's expertise, we can further accelerate the development of groundbreaking ag-biological products that will provide innovative solutions to farmers around the world."
"This transaction reflects Evogene's ongoing strategy to unlock the value of its assets for the benefit of its shareholders," said Ofer Haviv, CEO of Evogene. "We are confident that the integration of Lavie Bio's activities into ICL will significantly advance the global ag-biologicals field and drive impactful innovation in agriculture."
About Lavie Bio Ltd.
Lavie Bio, a subsidiary of Evogene Ltd., aims to improve food quality, sustainability, and agriculture productivity through the introduction of microbiome-based ag-biological products. Lavie Bio utilizes a proprietary computational predictive platform, the BDD platform, powered by Evogene's proprietary MicroBoost AI tech-engine, harnessing the power of big data, artificial intelligence, and advanced informatics, for the discovery, optimization and development of bio-stimulant and bio-pesticide products.
For more information, please visit www.lavie-bio.com.
About Evogene Ltd.
Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase probability of success while reducing development time and cost. Evogene established three unique technological engines – MicroBoost AI, ChemPass AI and GeneRator AI – leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences. Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, Evogene's main subsidiaries utilize the technological engines to develop human microbiome-based therapeutics by Biomica Ltd., ag-chemicals by AgPlenus Ltd. and ag-biologicals by Lavie Bio Ltd. For more information, please visit www.evogene.com.
Forward Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "hopes" "intends", "anticipates", "plans", "believes", "scheduled", "estimates", "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when they discuss the fulfilment of the closing conditions to the transaction, ICL and Lavie Bio's ability to accelerate the development of groundbreaking ag-biological products, and the statement that the integration of Lavie Bio's activities into ICL will significantly advance the global ag-biologicals field and drive impactful innovation in agriculture. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance, or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Evogene Investors Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
Logo - https://mma.prnewswire.com/media/945133/lavie_bio.jpg
Logo - https://mma.prnewswire.com/media/1947468/Evogene.jpg
View original content:https://www.prnewswire.com/news-releases/icl-to-acquire-the-activity-of-evogenes-subsidiary-lavie-bio-302433235.html
SOURCE Lavie Bio
FAQ
What assets is ICL acquiring from Evogene's Lavie Bio subsidiary?
When will the ICL-Lavie Bio acquisition (EVGN) close?
What happens to Lavie Bio's existing partnership agreements after the ICL acquisition?
How long have ICL and Lavie Bio (EVGN) been collaborating before the acquisition?
